Superseded public profile

FDA-approved↗Metabolic↗

Superseded · version 3: Glucagon↗

Related names recorded in this version: Gvoke VialDx↗

A peptide hormone. The cited U.S. label distinguishes Gvoke for severe hypoglycemia from Gvoke VialDx for diagnostic use.↗

This is preserved historical wording.
It is no longer the current profile. Read the canonical profile and its correction notice.
Correction · September 15, 2026

The previous summary described this only as an emergency-treatment label. We now distinguish Gvoke's severe-hypoglycemia indication from Gvoke VialDx's diagnostic indication in the same cited label. 1

What this version reported

The cited label describes subcutaneous Gvoke for severe hypoglycemia in people with diabetes aged two years and older, and intravenous Gvoke VialDx as a diagnostic aid in adults. The product, route and indication must remain distinct.↗

Organizations named in cited records:
  • U.S. National Library of Medicine↗

Sources for this version

  1. 1
    GVOKE VIALDX (glucagon) injection, solution · SPL version 2 · published 2026-07-09 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026